Medicus Pharma cleared to launch Phase 2b Teverelix study in Prostate Cancer

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company has received “study may proceed” clearance from the U.S. Food and Drug Administration to initiate ...

Medicus Pharma receives FDA clearance to proceed with Phase 2b prostate cancer study

Medicus Pharma (NASDAQ:MDCX) announced that it has received “study may proceed” clearance from the US Food and Drug ...
CURE

FDA Clears Phase 2b Study of Teverelix in Advanced Prostate Cancer

The phase 2b study is an open-label trial that will enroll 40 men with advanced prostate cancer who are appropriate candidates for ADT. Participants will receive an initial loading dose of teverelix ...